Zimbabwe has rejected a substantial US health deal worth $367m (272 million pounds) over five years due to Washington's demand for sensitive information.
This rejection was revealed after a internal memorandum dated December was leaked, revealing that Head of State Emmerson Mnangagwa felt the arrangement was "lopsided".
An official representative has since clarified that the US was requesting health data for scientific study and profit while refused to share the resulting advantages from any future treatments.
"We are forced to start the difficult and regrettable process of scaling back our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had provided more than $1.9bn in health funding to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has appealed for further talks to secure a agreement suitable to all parties so the nation's critical HIV treatment initiative can proceed.
Broader Context
This development comes after a comparable case in Kenya, where a high court blocked a related health funding agreement after concerns were filed about the security of citizens' health data.
Since resuming office recently, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had managed assistance for the American government, but Trump stated its spending was "wasteful" and his government was seeking direct bilateral agreements to boost transparency and accountability.
According to reports, 16 African countries have so far signed these new health pacts, representing over $18.3bn of fresh investment.
Specifics of the Declined Deal
This assistance for Zimbabwe was intended to gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this collaboration would have delivered immense advantages for Zimbabwean communities, especially the 1.2 million presently receiving antiretroviral therapy via US-supported programmes," the Ambassador added.
However, official spokesman Nick Mangwana argued the proposed deal was "unequal".
"Zimbabwe was being asked to share its biological resources and data over an extended period, without any equivalent assurance of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that provided information," Mangwana explained.
"In essence, our nation would supply the raw materials for scientific discovery without any certainty that the final treatments would be available to our citizens should a new health crisis emerge."
Sovereignty and Global Health
He also noted that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one health agreements were undermining structures previously set up via the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework created to deal with potential global health emergencies.
"This system is designed to ensure that when a nation contributes its data, the benefits – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the capability to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We welcome ongoing discussions with our American counterparts on how future collaboration could be designed in a way that honours the sovereignty and dignity of both nations."
Health Experts Reaction
Medical experts said it understood the government's concerns, but recommended that talks should continue considering much of the country's HIV programmes were funded by external financing.
"Where technical issues arise, including those involving data governance or agreement terms, these can frequently be resolved via detailed discussion and negotiated safeguards," it said.
This impasse underscores the ongoing challenges between receiving much-needed foreign assistance and protecting local interests in an increasingly data-driven world.